Literature DB >> 9844631

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.

D Yu1, T Jing, B Liu, J Yao, M Tan, T J McDonnell, M C Hung.   

Abstract

Overexpression of the receptor tyrosine kinase p185ErbB2 confers Taxol resistance in breast cancers. Here, we investigated the underlying mechanisms and found that overexpression of p185ErbB2 inhibits Taxol-induced apoptosis. Taxol activates p34Cdc2 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M phase and, subsequently, apoptosis. A chemical inhibitor of p34Cdc2 and a dominant-negative mutant of p34Cdc2 blocked Taxol-induced apoptosis in these cells. Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. In p21Cip1 antisense-transfected MDA-MB-435 cells or in p21-/- MEF cells, p185ErbB2 was unable to inhibit Taxol-induced apoptosis. Therefore, p21Cip1 participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in p185ErbB2-overexpressing breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844631     DOI: 10.1016/s1097-2765(00)80157-4

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  68 in total

Review 1.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  FoxM1 mediates resistance to herceptin and paclitaxel.

Authors:  Janai R Carr; Hyun Jung Park; Zebin Wang; Megan M Kiefer; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

3.  HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

Authors:  E Laughner; P Taghavi; K Chiles; P C Mahon; G L Semenza
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

Review 4.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 5.  NF-kappaB in pancreatic cancer.

Authors:  Guido M Sclabas; Shuichi Fujioka; Christian Schmidt; Douglas B Evans; Paul J Chiao
Journal:  Int J Gastrointest Cancer       Date:  2003

6.  Nutlin's two roads toward apoptosis.

Authors:  Qi Zhang; Hua Lu
Journal:  Cancer Biol Ther       Date:  2010-09-24       Impact factor: 4.742

7.  Subtype and pathway specific responses to anticancer compounds in breast cancer.

Authors:  Laura M Heiser; Anguraj Sadanandam; Wen-Lin Kuo; Stephen C Benz; Theodore C Goldstein; Sam Ng; William J Gibb; Nicholas J Wang; Safiyyah Ziyad; Frances Tong; Nora Bayani; Zhi Hu; Jessica I Billig; Andrea Dueregger; Sophia Lewis; Lakshmi Jakkula; James E Korkola; Steffen Durinck; François Pepin; Yinghui Guan; Elizabeth Purdom; Pierre Neuvial; Henrik Bengtsson; Kenneth W Wood; Peter G Smith; Lyubomir T Vassilev; Bryan T Hennessy; Joel Greshock; Kurtis E Bachman; Mary Ann Hardwicke; John W Park; Laurence J Marton; Denise M Wolf; Eric A Collisson; Richard M Neve; Gordon B Mills; Terence P Speed; Heidi S Feiler; Richard F Wooster; David Haussler; Joshua M Stuart; Joe W Gray; Paul T Spellman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-14       Impact factor: 11.205

Review 8.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

9.  Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.

Authors:  Débora Rosa Bublik; Massimiliano Scolz; Gianluca Triolo; Martín Monte; Claudio Schneider
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

10.  Trastuzumab for the treatment of salivary duct carcinoma.

Authors:  Sewanti A Limaye; Marshall R Posner; Jeffrey F Krane; Maria Fonfria; Jochen H Lorch; Deborah A Dillon; Aditya V Shreenivas; Roy B Tishler; Robert I Haddad
Journal:  Oncologist       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.